Cerebral Small Vessel Disease and Metabolism: Risk Factors, Therapeutic Targets, and Future Directions

doi:10.3969/j.issn.1673-5765.2024.12.005

Abstract

Abstract: It is crucial to identify the metabolic risk factors of cerebral small vessel disease (CSVD) and implement timely and systematic management. Currently, the correlation between residual metabolic risk factors and CSVD is still controversial, and there’s a lack of evidence-based support for the clinical efficacy of targeting risk factors in treating CSVD. This paper comprehensively analyzes the correlation between residual metabolic risk factors such as inflammation, gut microbiota dysbiosis, hyperhomocysteinemia, and hyperuricemia with the occurrence and development of CSVD. It further explores potential therapeutic options targeting metabolic risk factors, emphasizes the important role of metabolomics in the discovery of novel metabolic biomarkers and the establishment of risk prediction models for CSVD, and looks forward to future research directions, to provide a theoretical basis for the early diagnosis, mechanism exploration, risk factor management, and comprehensive multidisciplinary management of CSVD.

Key words: Cerebral small vessel disease; Metabolic risk factor; Therapeutic target; Biomarker; Comprehensive multidisciplinary management

摘要： 明确脑小血管病（cerebral small vessel disease，CSVD）的代谢危险因素并进行及时、系统的管控至关重要。目前残余代谢危险因素与CSVD的相关性尚存争议，而靶向危险因素治疗CSVD的临床效果尚缺乏循证依据。本文综合分析炎症、肠道菌群紊乱、高同型半胱氨酸血症及高尿酸血症等残余代谢危险因素与CSVD发生、发展的相关性，进一步探讨靶向代谢危险因素的潜在治疗方案，强调代谢组学在CSVD新型代谢生物标志物发现和风险预测模型建立中的重要作用，并展望未来研究方向，为CSVD的早期诊断、机制探索、危险因素管控和多学科综合管理提供理论依据。

关键词: 脑小血管病; 代谢危险因素; 治疗靶点; 生物标志物; 多学科综合管理

CLC Number:

QIU Yue, XU Yang, XUE Jing, XU Jie, WANG Yilong. Cerebral Small Vessel Disease and Metabolism: Risk Factors, Therapeutic Targets, and Future Directions[J]. Chinese Journal of Stroke, 2024, 19(12): 1392-1399.

邱悦, 徐阳, 薛婧, 许杰, 王伊龙. 脑小血管病与代谢：危险因素、治疗靶点和未来方向[J]. 中国卒中杂志, 2024, 19(12): 1392-1399.

References

[1] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国脑小血管病诊治指南2020[J]. 中华神经科杂志，2022，55（8）：807-818.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guideline for diagnosis and treatment of cerebral small vessel disease 2020[J]. Chin J Neurol，2022，55（8）：807-818.
[2] TSAO C W，ADAY A W，ALMARZOOQ Z I，et al. Heart disease and stroke statistics—2022 update：a report from the American Heart Association[J/OL]. Circulation，2022，145（8）：e153-e639[2024-10-08]. https://doi.org/10.1161/CIR.0000000000001052.
[3] 许杰，王拥军. 代谢性脑血管病：概念、方法、挑战和未来方向[J]. 中国卒中杂志，2023，18（6）：617-627.
XU J，WANG Y J. Cerebro-metabolic disease：concept，method，challenge and future directions[J]. Chin J Stroke，2023，18（6）：617-627.
[4] 张枘南，王伊龙. 脑小血管病与卒中防治的“异”与“同”[J]. 中风与神经疾病杂志，2024，41（1）：7-13.
ZHANG R N，WANG Y L. Differences and similarities in the prevention and treatment of cerebral small vessel disease and stroke[J]. Journal of Apoplexy and Nervous Diseases，2024，41（1）：7-13.
[5] VAN DIJK E J，PRINS N D，VERMEER S E，et al. C-reactive protein and cerebral small-vessel disease：the Rotterdam scan study[J]. Circulation，2005，112（6）：900-905.
[6] JIANG L L，CAI X L，YAO D X，et al. Association of inflammatory markers with cerebral small vessel disease in community-based population[J/OL]. J Neuroinflammation，2022，19（1）：106[2024-10-08]. https://doi.org/10.1186/s12974-022-02468-0.
[7] ZHANG D D，CAO Y，MU J Y，et al. Inflammatory biomarkers and cerebral small vessel disease：a community-based cohort study[J]. Stroke Vasc Neurol，2022，7（4）：302-309.
[8] NAM K W，KWON H M，JEONG H Y，et al. Monocyte to high-density lipoprotein cholesterol ratio is associated with cerebral small vessel diseases[J/OL]. BMC Neurol，2024，24（1）：18[2024-10-08]. https://doi.org/10.1186/s12883-023-03524-9.
[9] TSAI H H，CHEN Y F，YEN R F，et al. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau[J]. Brain，2021，144（11）：3371-3380.
[10] HU X，XIAO Z S，SHEN Y Q，et al. SERPINA3：a novel inflammatory biomarker associated with cerebral small vessel disease burden in ischemic stroke[J/OL]. CNS Neurosci Ther，2024，30（3）：e14472[2024-10-08]. https://doi.org/10.1111/cns.14472.
[11] MU L，JIANG L M，CHEN J，et al. Serum inflammatory factors and oxidative stress factors are associated with increased risk of frailty and cognitive frailty in patients with cerebral small vessel disease[J/OL]. Front Neurol，2021，12：786277[2024-10-08]. https://doi.org/10.3389/fneur.2021.786277.
[12] SHAN L L，WANG Y L，QIAO T C，et al. Association of serum interleukin-8 and serum amyloid A with anxiety symptoms in patients with cerebral small vessel disease[J/OL]. Front Neurol，2022，13：938655[2024-10-08]. https://doi.org/10.3389/fneur.2022.938655.
[13] HU M Y，LI T M，MA X M，et al. Macrophage lineage cells-derived migrasomes activate complement-dependent blood-brain barrier damage in cerebral amyloid angiopathy mouse model[J/OL]. Nat Commun，2023，14（1）：3945[2024-10-08]. https://doi.org/10.1038/s41467-023-39693-x.
[14] ZHANG M Y，LAN X Y，GAO Y，et al. Activation of NLRP3 inflammasome in a rat model of cerebral small vessel disease[J]. Exp Brain Res，2024，242（6）：1387-1397.
[15] MANSO Y，HOLLAND P R，KITAMURA A，et al. Minocycline reduces microgliosis and improves subcortical white matter function in a model of cerebral vascular disease[J]. Glia，2018，66（1）：34-46.
[16] LI L，HE G J，SHI M Y，et al. Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis（BCAS）[J/OL]. Eur J Pharmacol，2023，957：176036[2024-10-08]. https://doi.org/10.1016/j.ejphar.2023.176036.
[17] BROWN R B，TOZER D J，LOUBIÈRE L，et al. Minocycline to reduce inflammation and blood-brain barrier leakage in small vessel disease（MINERVA）：a phase Ⅱ，randomized，double-blind，placebo-controlled experimental medicine trial[J]. Alzheimers Dement，2024，20（6）：3852-3863.
[18] SHI Y C，ZHAO E，LI L，et al. Alteration and clinical potential in gut microbiota in patients with cerebral small vessel disease[J/OL]. Front Cell Infect Microbiol，2023，13：1231541[2024-10-08]. https://doi.org/10.3389/fcimb.2023.1231541.
[19] HUANG C J，ZHANG Y Y，LIU Y，et al. A bidirectional Mendelian randomization study of gut microbiota and cerebral small vessel disease[J]. J Nutr，2024，154（7）：1994-2005.
[20] CHEN Y Y，XU J，PAN Y S，et al. Association of trimethylamine N-oxide and its precursor with cerebral small vessel imaging markers[J/OL]. Front Neurol，2021，12：648702[2024-10-08]. https://doi.org/10.3389/fneur.2021.648702.
[21] LIU S，MEN X J，GUO Y，et al. Gut microbes exacerbate systemic inflammation and behavior disorders in neurologic disease CADASIL[J/OL]. Microbiome，2023，11（1）：202[2024-10-08]. https://doi.org/10.1186/s40168-023-01638-3.
[22] HUANG J Y，LIU S X，LI P J，et al. Multi-omics analysis of gut-brain axis reveals novel microbial and neurotransmitter signatures in patients with arteriosclerotic cerebral small vessel disease[J/OL]. Pharmacol Res，2024，208：107385[2024-10-08]. https://doi.org/10.1016/j.phrs.2024.107385.
[23] CAI W，CHEN X D，MEN X J，et al. Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγt[J/OL]. Sci Adv，2021，7（4）：eabe4827[2024-10-08]. https://doi.org/10.1126/sciadv.abe4827.
[24] XU H P，XIAO H，TANG Q Q. Lipopolysaccharide-induced intestinal inflammation on AIM2-mediated pyroptosis in the brain of rats with cerebral small vessel disease[J/OL]. Exp Neurol，2024，375：114746[2024-10-08]. https://doi.org/10.1016/j.expneurol.2024.114746.
[25] WANG X Y，SUN G Q，FENG T，et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression[J]. Cell Res，2019，29（10）：787-803.
[26] NAM K W，KWON H M，JEONG H Y，et al. Serum homocysteine level is related to cerebral small vessel disease in a healthy population[J/OL]. Neurology，2019，92（4）：e317-e325[2024-10-08]. https://doi.org/10.1212/WNL.0000000000006816.
[27] CAO Y Z，SU N，ZHANG D D，et al. Correlation between total homocysteine and cerebral small vessel disease：a Mendelian randomization study[J]. Eur J Neurol，2021，28（6）：1931-1938.
[28] KLOPPENBORG R P，GEERLINGS M I，VISSEREN F L，et al. Homocysteine and progression of generalized small-vessel disease：the SMART-MR study[J]. Neurology，2014，82（9）：777-783.
[29] LIU C H，GAO Y，SONG B，et al. Elevated serum homocysteine associated with distal type of single small subcortical infarction[J]. Curr Neurovasc Res，2020，17（5）：629-635.
[30] TENG Z J，FENG J，LIU R H，et al. Cerebral small vessel disease mediates the association between homocysteine and cognitive function[J/OL]. Front Aging Neurosci，2022，14：868777[2024-10-08]. https://doi.org/10.3389/fnagi.2022.868777.
[31] CAVALIERI M，SCHMIDT R，CHEN C，et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke：the vitamins to prevent stroke（VITATOPS）MRI-substudy[J]. Stroke，2012，43（12）：3266-3270.
[32] LIU R，HAO M，HUI J，et al. Effect of hyperbaric oxygen combined with folic acid on clinical efficacy and cognitive function in patients with cerebral small vessel disease[J]. Am J Transl Res，2023，15（3）：1897-1904.
[33] CROSTA F，OCCHIUZZI U，PASSALACQUA G，et al. Association between the serum uric acid levels and lacunar infarcts in the elderly[J]. J Mol Neurosci，2018，65（3）：385-390.
[34] YANG S N，ZHANG X Y，YUAN J L，et al. Serum uric acid is independently associated with enlarged perivascular spaces[J/OL]. Sci Rep，2017，7（1）：16435[2024-10-08]. https://doi.org/10.1038/s41598-017-16715-5.
[35] JEONG S M，YOO T G，NAM Y S，et al. Sex-dependent effects of uric acid on cerebral microbleed：a cross-sectional study in the general population[J]. Eur J Neurol，2017，24（10）：1300-1306.
[36] SCHRETLEN D J，INSCORE A B，VANNORSDALL T D，et al. Serum uric acid and brain ischemia in normal elderly adults[J]. Neurology，2007，69（14）：1418-1423.
[37] VANNORSDALL T D，JINNAH H A，GORDON B，et al. Cerebral ischemia mediates the effect of serum uric acid on cognitive function[J]. Stroke，2008，39（12）：3418-3420.
[38] LV H，SUN J，ZHANG T，et al. Associations of serum uric acid variability with neuroimaging metrics and cognitive decline：a population-based cohort study[J/OL]. BMC Med，2024，22（1）：256[2024-10-08]. https://doi.org/10.1186/s12916-024-03479-9.
[39] YU L，YI M，GUO J Y，et al. Lower serum uric acid and impairment of right cerebral hemisphere structural brain networks are related to depressive symptoms in cerebral small vessel disease：a cross-sectional study[J/OL]. Heliyon，2024，10（6）：e27947[2024-10-08]. https://doi.org/10.1016/j.heliyon.2024. e27947.
[40] YANG L，LV P，AI W P，et al. Lipidomic analysis of plasma in patients with lacunar infarction using normal-phase/reversed-phase two-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry[J]. Anal Bioanal Chem，2017，409（12）：3211-3222.
[41] HARSHFIELD E L，SANDS C J，TULADHAR A M，et al. Metabolomic profiling in small vessel disease identifies multiple associations with disease severity[J]. Brain，2022，145（7）：2461-2471.
[42] HARSHFIELD E L，MARKUS H S. Association of baseline metabolomic profiles with incident stroke and dementia and with imaging markers of cerebral small vessel disease[J/OL]. Neurology，2023，101（5）：e489-e501[2024-10-08]. https://doi.org/10.1212/WNL.0000000000207458.